Hai‐Bo Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hai‐Bo Hu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Bo Min
Department of Thoracic Surgery, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China
2 shared publicationsChuxu Wang
Department of Thoracic Surgery, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China
2 shared publicationsJie Huang
Department of Thoracic Surgery Renmin Hospital of Wuhan University, Wuchang District Wuhan China
2 shared publicationsKoufeng Shao
Department of Oncology, Huai’an Chuzhou Hospital of Traditional Chinese Medicine, Zhongda Hospital Group Hospital Affiliated to Southeast University, Huai’an, 223001, China
2 shared publicationsWei Lei
Department of Respiratory Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 shared publications- Xiaofeng Tian
Department of Thoracic Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical University, The Second People’s Hospital of Huai’an, Huai’an, 223001, China
2 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (5) , 2966-2980
Sublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ia non-small cell lung cancer
Background: For individuals aged 80 years and older with early-stage non-small cell lung cancer (NSCLC), prior research has indicated that surgical intervention accompanied by lymphadenectomy may offer superior long-term survival outcomes compared to radiotherapy; however, the selection of the appropriate surgical approach continues to be a subject of debate. So, our aim is to compare overall survival (OS) differences between two surgical modalities (lobectomy and sublobar resection) in patients aged 80 years and older with pathological stage Ia NSCLC according to the 8th edition of the tumor-node-metastasis (TNM) staging system. Methods: Patients aged ≥80 years with pathological stage Ia (T1N0M0) NSCLC from 2004 to 2021 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Patients were assigned to either the lobectomy or sublobar resection group. Optimal cutoff values for lymph nodes examined (LNE) were determined using X-Tile software, and lymph node status was classified into low dissection (1 to 5 lymph nodes) and high dissection (6 or more lymph nodes) groups. Confounding factors were controlled through propensity score matching (PSM) analysis, and OS results were analyzed using the Kaplan-Meier method. Survival-related factors were identified using multivariate Cox regression analysis. Results: A total of 1,735 patients were identified, with 30.0% in the sublobar resection group and 70.0% in the lobectomy group. The OS of the lobectomy group was significantly higher than that of the sublobar resection group (P=0.02). The 1-, 3-, and 5-year OS rates were 90.79%, 71.38%, and 56.60% for the sublobar resection group, respectively, compared to 89.87%, 76.88%, and 60.94% for the lobectomy group. In multivariate Cox regression analysis, the high lymph node dissection group demonstrated better prognosis [hazard ratio (HR) =0.796; 95% confidence interval (CI): 0.690–0.919; P=0.002]. Younger age, female sex, adenocarcinoma histology, and smaller tumor sizes were independent prognostic factors for improved OS. After PSM, no significant difference in OS was observed between the two groups (P=0.28), with 1-, 3-, and 5-year OS rates of 87.69%, 76.43%, and 56.41% in the lobectomy group, and 90.21%, 70.54%, and 55.65% in the sublobar resection group. Multivariate Cox regression indicated that the high lymph node dissection group had a better prognosis (HR =0.765; 95% CI: 0.620–0.944; P=0.01). Additionally, younger age and female sex were identified as independent prognostic factors for better OS. Conclusions: For patients aged 80 years and older diagnosed with stage Ia NSCLC, it is recommended that sublobar resection be performed in conjunction with the dissection of a minimum of six lymph nodes.
- 1 May 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (5) , 2966-2980
Open AccessSublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ia non-small cell lung cancer
Background: For individuals aged 80 years and older with early-stage non-small cell lung cancer (NSCLC), prior research has indicated that surgical intervention accompanied by lymphadenectomy may offer superior long-term survival outcomes compared to radiotherapy; however, the selection of the appropriate surgical approach continues to be a subject of debate. So, our aim is to compare overall survival (OS) differences between two surgical modalities (lobectomy and sublobar resection) in patients aged 80 years and older with pathological stage Ia NSCLC according to the 8th edition of the tumor-node-metastasis (TNM) staging system. Methods: Patients aged ≥80 years with pathological stage Ia (T1N0M0) NSCLC from 2004 to 2021 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Patients were assigned to either the lobectomy or sublobar resection group. Optimal cutoff values for lymph nodes examined (LNE) were determined using X-Tile software, and lymph node status was classified into low dissection (1 to 5 lymph nodes) and high dissection (6 or more lymph nodes) groups. Confounding factors were controlled through propensity score matching (PSM) analysis, and OS results were analyzed using the Kaplan-Meier method. Survival-related factors were identified using multivariate Cox regression analysis. Results: A total of 1,735 patients were identified, with 30.0% in the sublobar resection group and 70.0% in the lobectomy group. The OS of the lobectomy group was significantly higher than that of the sublobar resection group (P=0.02). The 1-, 3-, and 5-year OS rates were 90.79%, 71.38%, and 56.60% for the sublobar resection group, respectively, compared to 89.87%, 76.88%, and 60.94% for the lobectomy group. In multivariate Cox regression analysis, the high lymph node dissection group demonstrated better prognosis [hazard ratio (HR) =0.796; 95% confidence interval (CI): 0.690–0.919; P=0.002]. Younger age, female sex, adenocarcinoma histology, and smaller tumor sizes were independent prognostic factors for improved OS. After PSM, no significant difference in OS was observed between the two groups (P=0.28), with 1-, 3-, and 5-year OS rates of 87.69%, 76.43%, and 56.41% in the lobectomy group, and 90.21%, 70.54%, and 55.65% in the sublobar resection group. Multivariate Cox regression indicated that the high lymph node dissection group had a better prognosis (HR =0.765; 95% CI: 0.620–0.944; P=0.01). Additionally, younger age and female sex were identified as independent prognostic factors for better OS. Conclusions: For patients aged 80 years and older diagnosed with stage Ia NSCLC, it is recommended that sublobar resection be performed in conjunction with the dissection of a minimum of six lymph nodes.
- Top Cited PapersOpen Access
- 6 January 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 76, 695-713
Targeting macrophages in cancer immunotherapy: Frontiers and challenges
- 6 January 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 76, 695-713
Top Cited PapersOpen AccessTargeting macrophages in cancer immunotherapy: Frontiers and challenges
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (3) , 653-663
Loss of TNFRSF21 induces cisplatin sensitivity in lung adenocarcinoma
Background: Despite the identification of numerous therapeutic targets in lung cancer, achieving significant efficacy has been challenging. TNFRSF21 plays an important role in various cancers. We investigated the function of... | Find, read and cite all the research you need on Tech Science Press
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (3) , 653-663
Open AccessLoss of TNFRSF21 induces cisplatin sensitivity in lung adenocarcinoma
Background: Despite the identification of numerous therapeutic targets in lung cancer, achieving significant efficacy has been challenging. TNFRSF21 plays an important role in various cancers. We investigated the function of... | Find, read and cite all the research you need on Tech Science Press
- Open Access
- 15 December 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (6) , 1754-1765
Circular RNA hsa_circ_0008003 facilitates tumorigenesis and development of non‐small cell lung carcinoma via modulating miR‐488/ZNF281 axis
As one of the most aggressive malignancies, non‐small cell lung carcinoma (NSCLC) has high risks of death. It has been demonstrated that circRNAs accelerate NSCLC progression, but the underlying molecular mechanisms of circRNAs in NSCLC were still obscure. In the first place, the circRNA microarray of NSCLC was investigated in this study, and hsa_circ_0008003 (circ‐0008003) was chosen as the research object. Then, it was unveiled that the expression of circ‐0008003 examined via qRT‐PCR was elevated in tumour tissues relative to the non‐tumour tissues, which was associated with TNM stage and lymphatic metastasis in NSCLC. Additionally, the prognosis of NSCLC patients with high circ‐0008003 level was poor. Besides, circ‐0008003 silencing dampened the invasion and proliferation of NSCLC cells. Next, according to the mechanistic studies, circ‐0008003 functioned as a ceRNA of ZNF281 in NSCLC by acting as the endogenous sponge for miR‐488, which was proved to be a tumour suppressor in NSCLC. Additionally, ZNF281 overexpression and miR‐488 suppression recovered the influences of repressed circ‐0008003 on NSCLC cellular processes. It was validated in this research that circ‐0008003 triggered tumour formation in NSCLC, which was adjusted via miR‐488/ZNF281 axis, casting a novel light on the resultful target for treating NSCLC and predicting the prognosis.
- 15 December 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (6) , 1754-1765
Open AccessCircular RNA hsa_circ_0008003 facilitates tumorigenesis and development of non‐small cell lung carcinoma via modulating miR‐488/ZNF281 axis
As one of the most aggressive malignancies, non‐small cell lung carcinoma (NSCLC) has high risks of death. It has been demonstrated that circRNAs accelerate NSCLC progression, but the underlying molecular mechanisms of circRNAs in NSCLC were still obscure. In the first place, the circRNA microarray of NSCLC was investigated in this study, and hsa_circ_0008003 (circ‐0008003) was chosen as the research object. Then, it was unveiled that the expression of circ‐0008003 examined via qRT‐PCR was elevated in tumour tissues relative to the non‐tumour tissues, which was associated with TNM stage and lymphatic metastasis in NSCLC. Additionally, the prognosis of NSCLC patients with high circ‐0008003 level was poor. Besides, circ‐0008003 silencing dampened the invasion and proliferation of NSCLC cells. Next, according to the mechanistic studies, circ‐0008003 functioned as a ceRNA of ZNF281 in NSCLC by acting as the endogenous sponge for miR‐488, which was proved to be a tumour suppressor in NSCLC. Additionally, ZNF281 overexpression and miR‐488 suppression recovered the influences of repressed circ‐0008003 on NSCLC cellular processes. It was validated in this research that circ‐0008003 triggered tumour formation in NSCLC, which was adjusted via miR‐488/ZNF281 axis, casting a novel light on the resultful target for treating NSCLC and predicting the prognosis.
- 16 April 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (10) , 18679-18687
Downregulation of lysyl oxidase‐like 4 LOXL4 by miR‐135a‐5p promotes lung cancer progression in vitro and in vivo
Aberrant microRNAs are widely identified in multiple cancers, including lung cancer. miR‐135a‐5p can function as a significant tumor regulator in diverse cancers via impacting multiple genes in oncogenic pathways. Nevertheless, the biological role of miR‐135a‐5p in lung cancer is poorly known. Here, we investigated its function in lung cancer. As exhibited, miR‐135a‐5p was elevated in lung cancer cells in contrast to BEAS‐2B cells. Then, we inhibited miR‐135a‐5p expression by transfecting LV‐anti‐miR‐135a‐5p into lung cancer cells. As displayed, miR‐135a‐5p was obviously reduced in A549 and H1299 cells. Knockdown of miR‐135a‐5p repressed lung cancer cell growth and cell proliferation. Meanwhile, cell colony formation capacity was depressed, cell apoptosis was enhanced and cell cycle progression was blocked in G1 phase by inhibition of miR‐135a‐5p in vitro. Additionally, the migration and invasion of A549 and H1299 cells was strongly depressed by LV‐anti‐miR‐135a‐5p. For another, by using informatics analysis, lysyl oxidase‐like 4 (LOXL4) was speculated as the downstream target of miR‐135a‐5p. We validated their direct correlation and moreover, overexpression of miR‐135a‐5p restrained LOXL4 levels in lung cancer cells. Subsequently, we proved that miR‐135a‐5p promoted lung cancer development via targeting LOXL4 by carrying out the in vivo assays. Taken these together, our study revealed miR‐135a‐5p might be indicated as a perspective for lung cancer via targeting LOXL4.
- 16 April 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (10) , 18679-18687
Downregulation of lysyl oxidase‐like 4 LOXL4 by miR‐135a‐5p promotes lung cancer progression in vitro and in vivo
Aberrant microRNAs are widely identified in multiple cancers, including lung cancer. miR‐135a‐5p can function as a significant tumor regulator in diverse cancers via impacting multiple genes in oncogenic pathways. Nevertheless, the biological role of miR‐135a‐5p in lung cancer is poorly known. Here, we investigated its function in lung cancer. As exhibited, miR‐135a‐5p was elevated in lung cancer cells in contrast to BEAS‐2B cells. Then, we inhibited miR‐135a‐5p expression by transfecting LV‐anti‐miR‐135a‐5p into lung cancer cells. As displayed, miR‐135a‐5p was obviously reduced in A549 and H1299 cells. Knockdown of miR‐135a‐5p repressed lung cancer cell growth and cell proliferation. Meanwhile, cell colony formation capacity was depressed, cell apoptosis was enhanced and cell cycle progression was blocked in G1 phase by inhibition of miR‐135a‐5p in vitro. Additionally, the migration and invasion of A549 and H1299 cells was strongly depressed by LV‐anti‐miR‐135a‐5p. For another, by using informatics analysis, lysyl oxidase‐like 4 (LOXL4) was speculated as the downstream target of miR‐135a‐5p. We validated their direct correlation and moreover, overexpression of miR‐135a‐5p restrained LOXL4 levels in lung cancer cells. Subsequently, we proved that miR‐135a‐5p promoted lung cancer development via targeting LOXL4 by carrying out the in vivo assays. Taken these together, our study revealed miR‐135a‐5p might be indicated as a perspective for lung cancer via targeting LOXL4.
- 25 February 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (9) , 16540-16548
Identification of the molecular subgroups in coronary artery disease by gene expression profiles
Coronary artery disease (CAD) is the most common type of cardiovascular disease and becomes a leading cause of death worldwide. Aiming to uncover the underlying molecular features for different types of CAD, we classified 352 CAD cases into three subgroups based on gene expression profiles, which were retrieved from the Gene Expression Omnibus database. Also, these subgroups present different expression patterns and clinical characteristics. To uncover the transcriptomic differences between the subgroups, weighted gene co‐expression analysis (WGCNA) was used and identified six subgroup‐specific WGCNA modules. Characterization of the WCGNA modules revealed that lipid metabolism pathways, specifically upregulated in subgroup I, might be an indicator of increased severity. Moreover, subgroup II was considered as an early‐stage of CAD because of normal‐like gene expression patterns. In contrast, the mammalian target of rapamycin signaling pathway was significantly upregulated in subgroup III. Although subgroups II and III did not have a significant prognostic difference, their intrinsic biological characteristics were highly different, suggesting that the transcriptome classification may represent risk factors of both age and the intrinsic biological characteristics. In conclusion, the transcriptome classification of CAD cases revealed that cases from different subgroups may have their unique gene expression patterns, indicating that patients in each subgroup should receive more personalized treatment.
- 25 February 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (9) , 16540-16548
Identification of the molecular subgroups in coronary artery disease by gene expression profiles
Coronary artery disease (CAD) is the most common type of cardiovascular disease and becomes a leading cause of death worldwide. Aiming to uncover the underlying molecular features for different types of CAD, we classified 352 CAD cases into three subgroups based on gene expression profiles, which were retrieved from the Gene Expression Omnibus database. Also, these subgroups present different expression patterns and clinical characteristics. To uncover the transcriptomic differences between the subgroups, weighted gene co‐expression analysis (WGCNA) was used and identified six subgroup‐specific WGCNA modules. Characterization of the WCGNA modules revealed that lipid metabolism pathways, specifically upregulated in subgroup I, might be an indicator of increased severity. Moreover, subgroup II was considered as an early‐stage of CAD because of normal‐like gene expression patterns. In contrast, the mammalian target of rapamycin signaling pathway was significantly upregulated in subgroup III. Although subgroups II and III did not have a significant prognostic difference, their intrinsic biological characteristics were highly different, suggesting that the transcriptome classification may represent risk factors of both age and the intrinsic biological characteristics. In conclusion, the transcriptome classification of CAD cases revealed that cases from different subgroups may have their unique gene expression patterns, indicating that patients in each subgroup should receive more personalized treatment.
- 11 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 14050-14057
miR‐210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase‐like 4
Accumulating evidence has revealed that various microRNAs are deregulated and involved in lung cancer development and metastasis. miR‐210 is implicated in several cancer progression. However, the detailed biological function and role of miR‐210 in lung adenocarcinoma remains unclear. Our current study was aimed to investigate the mechanism of miR‐210 in lung adenocarcinoma progression. We observed that miR‐210 was significantly upregulated in lung cancer cell lines (A549 and H1650) in comparison to BEAS‐2B cells. In addition, we found that miR‐210 was greatly elevated in lung adenocarcinoma tissues. Then, it was shown that overexpression of miR‐210 was able to promote lung cancer cell proliferation and colony formation ability while inhibitors of miR‐210 exhibited a reversed phenomenon. Subsequently, A549 and H1650 cell migration and invasion capacity were obviously restrained by miR‐210 inhibition whereas induced by miR‐210 mimics. Lysyl oxidase‐like 4 (LOXL4), a member of the secreted copper‐dependent amine oxidases has been found to be increased or decreased in different cancer types. Here, we confirmed that LOXL4 could serve as a downstream target of miR‐210 and miR‐210 promoted lung cancer progression via targeting LOXL4. In A549 and H1650 cells, knockdown of LOXL4 dramatically repressed lung cancer cell proliferation, migration, and invasion. In conclusion, our study implied that miR‐210 might indicate a new perspective for lung cancer.
- 11 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 14050-14057
miR‐210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase‐like 4
Accumulating evidence has revealed that various microRNAs are deregulated and involved in lung cancer development and metastasis. miR‐210 is implicated in several cancer progression. However, the detailed biological function and role of miR‐210 in lung adenocarcinoma remains unclear. Our current study was aimed to investigate the mechanism of miR‐210 in lung adenocarcinoma progression. We observed that miR‐210 was significantly upregulated in lung cancer cell lines (A549 and H1650) in comparison to BEAS‐2B cells. In addition, we found that miR‐210 was greatly elevated in lung adenocarcinoma tissues. Then, it was shown that overexpression of miR‐210 was able to promote lung cancer cell proliferation and colony formation ability while inhibitors of miR‐210 exhibited a reversed phenomenon. Subsequently, A549 and H1650 cell migration and invasion capacity were obviously restrained by miR‐210 inhibition whereas induced by miR‐210 mimics. Lysyl oxidase‐like 4 (LOXL4), a member of the secreted copper‐dependent amine oxidases has been found to be increased or decreased in different cancer types. Here, we confirmed that LOXL4 could serve as a downstream target of miR‐210 and miR‐210 promoted lung cancer progression via targeting LOXL4. In A549 and H1650 cells, knockdown of LOXL4 dramatically repressed lung cancer cell proliferation, migration, and invasion. In conclusion, our study implied that miR‐210 might indicate a new perspective for lung cancer.
- 14 December 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (7) , 11380-11390
Identification of microRNAs related to myocardial ischemic reperfusion injury
Previous studies have suggested that microRNAs (miRNAs) are associated with the progression of myocardial ischemic reperfusion (I/R) injury. However, inconsistent results have been obtained due to the differences in sequencing platform, control selection, and filtering conditions. To explore the key miRNAs in the pathogenesis of myocardial I/R injury and develop miRNA diagnostic biomarkers for myocardial I/R injury prevention, we performed a systematic analysis of publicly available myocardial I/R injury miRNA expression data and investigated the function of the signature miRNA. A total of 17 representative myocardial I/R injury miRNA datasets were extracted from the Google Scholar website and a systematic bioinformatics analysis was done. TargetScan software was used to predict the miRNA target genes, and functional enrichment and transcription factor binding analyses were performed on the target genes using the DAVID and Tfacts databases. In this study, a total of 10 signature miRNAs associated with myocardial I/R injury were identified, which included eight significantly upregulated miRNAs (miR‐let‐7b‐3p, miR‐let‐7c‐3p, miR‐15b‐3p, miR‐195‐3p, miR‐21‐5p, miR‐214‐5p, miR‐24‐3p, and miR‐320a) and two significantly downregulated miRNAs (miR‐126‐5p and miR‐499a‐5p). They had different influences on myocardial I/R injury. The upregulated target gene‐expressing signature messenger RNAs (mRNAs) were mainly involved in the transcriptional regulation process of GO: 0000122, negative regulation of transcription from RNA polymerase II promoter, and so on, while downregulated expression of signature mRNAs was mainly involved in GO:0070534, protein K63‐linked ubiquitination, and so forth. To summarize, 10 signature miRNAs of myocardial I/R injury pathogenesis were identified and their target genes and transcription factors were revealed, suggesting the potential novel therapeutic targets for myocardial I/R injury.
- 14 December 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (7) , 11380-11390
Identification of microRNAs related to myocardial ischemic reperfusion injury
Previous studies have suggested that microRNAs (miRNAs) are associated with the progression of myocardial ischemic reperfusion (I/R) injury. However, inconsistent results have been obtained due to the differences in sequencing platform, control selection, and filtering conditions. To explore the key miRNAs in the pathogenesis of myocardial I/R injury and develop miRNA diagnostic biomarkers for myocardial I/R injury prevention, we performed a systematic analysis of publicly available myocardial I/R injury miRNA expression data and investigated the function of the signature miRNA. A total of 17 representative myocardial I/R injury miRNA datasets were extracted from the Google Scholar website and a systematic bioinformatics analysis was done. TargetScan software was used to predict the miRNA target genes, and functional enrichment and transcription factor binding analyses were performed on the target genes using the DAVID and Tfacts databases. In this study, a total of 10 signature miRNAs associated with myocardial I/R injury were identified, which included eight significantly upregulated miRNAs (miR‐let‐7b‐3p, miR‐let‐7c‐3p, miR‐15b‐3p, miR‐195‐3p, miR‐21‐5p, miR‐214‐5p, miR‐24‐3p, and miR‐320a) and two significantly downregulated miRNAs (miR‐126‐5p and miR‐499a‐5p). They had different influences on myocardial I/R injury. The upregulated target gene‐expressing signature messenger RNAs (mRNAs) were mainly involved in the transcriptional regulation process of GO: 0000122, negative regulation of transcription from RNA polymerase II promoter, and so on, while downregulated expression of signature mRNAs was mainly involved in GO:0070534, protein K63‐linked ubiquitination, and so forth. To summarize, 10 signature miRNAs of myocardial I/R injury pathogenesis were identified and their target genes and transcription factors were revealed, suggesting the potential novel therapeutic targets for myocardial I/R injury.
- 14 December 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 2836-2846
NEAT1/hsa‐mir‐98‐5p/MAPK6 axis is involved in non–small‐cell lung cancer development
Long noncoding RNAs (lncRNAs) or microRNAs belong to the two most important noncoding RNAs and they are involved in a lot of cancers, including non–small‐cell lung cancer (NSCLC). Therefore, currently, we focused on the biological and clinical significance of lncRNA nuclear enriched abundant transcript 1 (NEAT1) and hsa‐mir‐98‐5p in NSCLC. It was observed that NEAT1 was upregulated while hsa‐mir‐98‐5p was downregulated respectively in NSCLC cell lines compared to human normal lung epithelial BES‐2B cells. Inhibition of NEAT1 can suppress the progression of NSCLC cells and hsa‐mir‐98‐5p can reverse this phenomenon. Bioinformatics search was used to elucidate the correlation between NEAT1 and hsa‐mir‐98‐5p. Additionally, a novel messenger RNA target of hsa‐mir‐98‐5p, mitogen‐activated protein kinase 6 (MAPK6), was predicted. Overexpression and knockdown studies were conducted to verify whether NEAT1 exhibits its biological functions through regulating hsa‐mir‐98‐5p and MAPK6 in vitro. NEAT1 was able to increase MAPK6 expression and hsa‐mir‐98‐5p mimics can inhibit MAPK6 via downregulating NEAT1 levels. We speculated that NEAT1 may act as a competing endogenous lncRNA to upregulate MAPK6 by attaching hsa‐mir‐98‐5p in lung cancers. Taken these together, NEAT1/hsa‐mir‐98‐5p/MAPK6 is involved in the development and progress in NSCLC. NEAT1 could be recommended as a prognostic biomarker and therapeutic indicator in NSCLC diagnosis and treatment.
- 14 December 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 2836-2846
NEAT1/hsa‐mir‐98‐5p/MAPK6 axis is involved in non–small‐cell lung cancer development
Long noncoding RNAs (lncRNAs) or microRNAs belong to the two most important noncoding RNAs and they are involved in a lot of cancers, including non–small‐cell lung cancer (NSCLC). Therefore, currently, we focused on the biological and clinical significance of lncRNA nuclear enriched abundant transcript 1 (NEAT1) and hsa‐mir‐98‐5p in NSCLC. It was observed that NEAT1 was upregulated while hsa‐mir‐98‐5p was downregulated respectively in NSCLC cell lines compared to human normal lung epithelial BES‐2B cells. Inhibition of NEAT1 can suppress the progression of NSCLC cells and hsa‐mir‐98‐5p can reverse this phenomenon. Bioinformatics search was used to elucidate the correlation between NEAT1 and hsa‐mir‐98‐5p. Additionally, a novel messenger RNA target of hsa‐mir‐98‐5p, mitogen‐activated protein kinase 6 (MAPK6), was predicted. Overexpression and knockdown studies were conducted to verify whether NEAT1 exhibits its biological functions through regulating hsa‐mir‐98‐5p and MAPK6 in vitro. NEAT1 was able to increase MAPK6 expression and hsa‐mir‐98‐5p mimics can inhibit MAPK6 via downregulating NEAT1 levels. We speculated that NEAT1 may act as a competing endogenous lncRNA to upregulate MAPK6 by attaching hsa‐mir‐98‐5p in lung cancers. Taken these together, NEAT1/hsa‐mir‐98‐5p/MAPK6 is involved in the development and progress in NSCLC. NEAT1 could be recommended as a prognostic biomarker and therapeutic indicator in NSCLC diagnosis and treatment.